Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Multidisciplinary management of bone metastases in renal cancer

Camillo Porta, MD, A. Moro University of Bari, Bari, Italy, highlights the importance of a multidisciplinary approach to treating patients with renal cancer who have bone metastasis, highlighting the need for systemic treatment, radiation therapy, orthopedic surgery, pain management, and bone-targeting agents. A comprehensive approach is necessary to address the various aspects of bone metastasis, including pain management and prevention of fractures. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Bone metastasis is a clear example of a need for a multidisciplinary approach to cancer patients because beyond the backbone of systemic treatment, always patients need the intervention of radiation therapies in order to irradiate those lesions which are critical or cause pain. Sometimes there is a need for an orthopedic surgeon to operate on the bone to prevent fractures or to treat fractures...

Bone metastasis is a clear example of a need for a multidisciplinary approach to cancer patients because beyond the backbone of systemic treatment, always patients need the intervention of radiation therapies in order to irradiate those lesions which are critical or cause pain. Sometimes there is a need for an orthopedic surgeon to operate on the bone to prevent fractures or to treat fractures. The need for the involvement of those treating pain, which is of course one of the most distressing symptoms a patient with bone metastasis has. And finally, we have to take into account also often the need for bone-targeting agents such as Zoledronic acid or Denosumab, which can complement the systemic treatment in these patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...